Recruiting

Testing a new blood clot medication for stroke patients receiving emergency stent placement

Plain-English translation of NCT06813651 on ClinicalTrials.gov ↗ · Source last updated November 2025 · Translation generated July 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing a new medication called TBO-309 to see if it can help stroke patients who need emergency stent placement in their neck arteries. When doctors place a stent to restore blood flow during a stroke, blood clots can form on the stent, which is dangerous. This study will test whether TBO-309 can prevent those clots from forming and keep the stent working properly.

Stroke patients with certain types of blockages need stents placed in their neck arteries during emergency treatment, but these stents can develop blood clots that are risky. Currently, doctors use strong blood-thinning medications to prevent clots, but these can increase the risk of dangerous bleeding. This trial aims to see if the new treatment can prevent clots effectively while causing fewer bleeding complications.

Do you qualify?

You likely qualify if…

you are at least 18 years old
you have been diagnosed with a specific type of stroke involving blockages in both your neck artery and a brain artery
brain imaging shows that part of your brain tissue can still be saved with emergency treatment
you have mild to moderate stroke symptoms (not completely unresponsive)
before your stroke, you were able to live independently or with minimal help

You likely don't qualify if…

you have advanced dementia or were severely disabled before your stroke
you have uncontrolled high blood pressure that hasn't responded to medication
you have had bleeding in your brain within the last 3 months
you have a serious liver disease or known bleeding disorder
you have a life expectancy of less than 90 days due to another medical condition

What participation looks like

If you qualify, you would receive the study medication (TBO-309) as an intravenous infusion before your emergency stent procedure. The treatment starts with a quick injection, followed by a 3-hour drip of the medication. You would then undergo the standard emergency stroke treatment with stent placement, and doctors would monitor you closely with follow-up imaging at 24–36 hours to check that the stent is working properly and no bleeding has occurred.

AI-generated summary from trial data · Jul 19, 2026 · Not medical advice

Testing a new blood clot medication for stroke patients receiving emergency stent placement

What is this trial?

Do you qualify?

What participation looks like

Trial locations(2 sites)